Close Association of Hypoadiponectinemia and Increased Insulin Resistance in Non-Obese Japanese Type 2 Diabetes with Visceral AdiposityHodaka Yamada1*, Daisuke Suzuki1, Masafumi Kakei1, Ikuyo Kusaka1, San-e Ishikawa2 and Kazuo Hara1
- *Corresponding Author:
- Hodaka Yamada, MD
Department of Medicine
Jichi Medical University Saitama Medical Center
1-847 Amanuma-cho, Omiya-ku
Saitama 330-8503, Japan
E-mail: [email protected]
Received date: September 26, 2016; Accepted date: October 07, 2016; Published date: October 14, 2016
Citation: Yamada H, Suzuki D, Kakei M, Kusaka I, Ishikawa S (2016) Close Association of Hypoadiponectinemia and Increased Insulin Resistance in Non- Obese Japanese Type 2 Diabetes with Visceral Adiposity. J Metabolic Synd 5:215.doi: 10.4172/2167-0943.1000215
Copyright: © 2016 Yamada H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: Visceral fat accumulation because of obesity plays a central role in metabolic syndrome and causes cardiovascular disease (CVD).
Methods: The aims of this study were to investigate associations between visceral fat accumulation and adipokines in non-obese type 2 diabetic patients.
Results: In total, 138 type 2 diabetic patients were enrolled, with a mean age of 64 years. Among the participants, 69 were males. We found that serum high-molecular-weight adiponectin level was decreased, C-reactive protein increased, and using homeostatic model assessment of insulin resistance was also increased in non-obese patients with visceral adiposity (body mass index: BMI, <25 kg/m2; visceral fat area: VFA, ≥ 100 cm2) compared with those without visceral adiposity (BMI, <25 kg/m2, VFA, <100 cm2). VFA in non-alcoholic fatty liver disease (NAFLD) was higher than in those with no NAFLD.
Conclusion: We demonstrated that visceral fat accumulation is a risk for CVD in non-obese diabetic patients with visceral adiposity.